The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
The FDA has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use...
The US patent on Diovan (valsartan) and the combination product Diovan HCT (valsartan plus the diuretic hydrochlorothiazide) from Novartis has...
Sevikar HCT (olmesartan medoxomil, amlodipine besylate plus hydrochlorothiazide) from Daiichi Sankyo Europe, the first three-in-one pill to treat Hypertension, has...
ANI Pharmaceuticals, Inc. announced that it has acquired the NDAs and U.S. rights to market Atacand, Atacand HCT, Arimidex, and...